moneyheap
LABU · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Direxion Daily S&P Biotech Bull 3X ETF (LABU) stock moving?
No news items or SEC filings were found for LABU in the relevant window, so this view rests only on the 30-day price and volume data. The fund is a 3x leveraged product, so daily moves are magnified. Over the 14 sessions shown, the close went from 229.18 on Oct 22 to 236.32 on Nov 10, a gain of about 3%, but the path was volatile. The stock peaked at 256.96 on Oct 29, then fell to 208.62 on Nov 5, a drop of about 20% in one session, with volume of 641,133 shares, roughly 1.9 times the period average of about 342,000. The Nov 5 close sat near the session low. It then rebounded to 245.11 by Nov 9 (about 17% off the low) before slipping 3.6% to 236.32 on Nov 10. The range of 204.54 to 268.00 is wide, and the Nov 5 selloff was the clearest volume event. Without a stated catalyst, the cause of that move is unknown, so the evidence points neither way strongly.
About Direxion Daily S&P Biotech Bull 3X ETF
LABU is a Direxion leveraged ETF, launched in May 2015, that aims to return 300% of the S&P Biotechnology Select Industry Index's performance each day, before fees. The index weights its holdings roughly equally, so small and mid-sized biotech companies count for much more here than in funds weighted by company size, and the 3x leverage makes the fund very volatile.
How the fund works
The fund gets most of its exposure through total-return swaps on the index, held alongside some of the biotech stocks themselves and cash or Treasury money-market funds. It resets its leverage every day, so over periods longer than one day its return can be very different from 3x the index's return. Choppy markets tend to wear down value, and the fund has lost money since it launched even though it has had strong years. The expense ratio is roughly 0.96%, and assets are approximately $650 million. Direxion's sister fund LABD aims for the opposite: -3x the index's daily move.
What usually moves LABU
- Overall biotech sector sentiment and XBI moves
- Interest rates and access to funding for small biotechs
- FDA drug approvals and clinical trial results
- Biotech mergers and acquisitions
- Drug-pricing policy and regulation